# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

> **NCT03731182** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 104 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13™

## Key facts

- **NCT ID:** NCT03731182
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-23
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-06-08
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731182, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03731182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*